1. Home
  2. REAL vs NKTX Comparison

REAL vs NKTX Comparison

Compare REAL & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The RealReal Inc.

REAL

The RealReal Inc.

HOLD

Current Price

$16.25

Market Cap

1.7B

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$1.87

Market Cap

129.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REAL
NKTX
Founded
2011
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
129.3M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
REAL
NKTX
Price
$16.25
$1.87
Analyst Decision
Buy
Strong Buy
Analyst Count
8
5
Target Price
$15.29
$13.25
AVG Volume (30 Days)
2.5M
665.2K
Earning Date
11-10-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$662,789,000.00
N/A
Revenue This Year
$17.10
N/A
Revenue Next Year
$10.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.30
N/A
52 Week Low
$4.61
$1.31
52 Week High
$16.41
$2.74

Technical Indicators

Market Signals
Indicator
REAL
NKTX
Relative Strength Index (RSI) 68.18 51.25
Support Level $15.81 $1.79
Resistance Level $16.41 $1.90
Average True Range (ATR) 0.77 0.06
MACD 0.09 0.01
Stochastic Oscillator 81.99 80.00

Price Performance

Historical Comparison
REAL
NKTX

About REAL The RealReal Inc.

The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: